Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Aytu Biopharma (AYTU) over the last 16 years, with Q4 2025 value amounting to -$2.6 million.

  • Aytu Biopharma's Net Cash Flow fell 99827.59% to -$2.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $9.6 million, marking a year-over-year increase of 100782.51%. This contributed to the annual value of $10.9 million for FY2025, which is 46743.87% up from last year.
  • Latest data reveals that Aytu Biopharma reported Net Cash Flow of -$2.6 million as of Q4 2025, which was down 99827.59% from $1.7 million recorded in Q3 2025.
  • Aytu Biopharma's 5-year Net Cash Flow high stood at $13.0 million for Q1 2021, and its period low was -$9.4 million during Q3 2021.
  • Over the past 5 years, Aytu Biopharma's median Net Cash Flow value was -$107000.0 (recorded in 2023), while the average stood at -$190150.0.
  • The largest annual percentage gain for Aytu Biopharma's Net Cash Flow in the last 5 years was 509471.54% (2025), contrasted with its biggest fall of 106320.35% (2025).
  • Over the past 5 years, Aytu Biopharma's Net Cash Flow (Quarter) stood at -$5.3 million in 2021, then rose by 18.05% to -$4.3 million in 2022, then soared by 89.94% to -$435000.0 in 2023, then surged by 166.67% to $290000.0 in 2024, then plummeted by 998.28% to -$2.6 million in 2025.
  • Its Net Cash Flow stands at -$2.6 million for Q4 2025, versus $1.7 million for Q3 2025 and $12.8 million for Q2 2025.